Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VGR-R01

Phase 3Small molecule

SShanghai Vitalgen BioPharma Co., Ltd.

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bietti Crystalline DystrophyActive, not recruiting

Bietti Crystalline DystrophyPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Bietti Crystalline Dystrophy

NCT06699108

Clinical

Trials by Indication[1]

Bietti Crystalline Dystrophy2 trials

Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy

Unknown status·—·Phase 1·NCT05399069·3 enrolled

Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy

Active, not recruiting·SShanghai Vitalgen BioPharma Co., Ltd.·Phase 3·NCT06699108·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VGR-R01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VGR-R01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VGR-R01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Vitalgen BioPharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Vitalgen BioPharma Co., Ltd.

Related News